Leber Congenital Amaurosis: A Guide for Families
Schedule Today
Who Gets LCA and Why
LCA is a rare condition, but it is important to understand who is at risk and how the condition is passed from parents to children. This knowledge helps families make informed decisions about genetic testing and family planning.
LCA affects approximately 1 in 40,000 newborns, with estimates ranging from 1 in 33,000 to 1 in 81,000 depending on the population studied. While it is considered a rare disease, its impact is significant because it often causes profound visual impairment from the very beginning of a child's life.
LCA is most often inherited in an autosomal recessive pattern. This means a child must receive one defective copy of the relevant gene from each parent to develop the condition. Parents who each carry one copy of the gene variant typically have no vision problems themselves. When both parents are carriers, each pregnancy carries a 25% chance that the child will inherit both defective copies and develop LCA.
A small number of LCA cases are caused by a dominant inheritance pattern, in which only one defective gene copy is needed to cause disease. The IMPDH1 and OTX2 genes follow this pattern. The CRX gene can cause either dominant or recessive disease depending on the specific mutation involved.
The primary risk factor for LCA is having parents who each carry a mutation in one of the associated genes. A family history of any inherited retinal disease, even without a confirmed LCA diagnosis, may indicate that family members could be carriers. Genetic counseling can help families understand their personal risk and explore options for future pregnancies.
Signs and Symptoms
LCA usually becomes noticeable in the earliest weeks or months of life. Recognizing the signs early is important because prompt referral leads to faster diagnosis and access to support services. The specific symptoms a child experiences can vary depending on which gene is involved.
A decrease in visual responsiveness is usually the first sign that something may be wrong. Parents may notice that their baby does not fix his or her gaze on faces or objects, or does not track moving things with their eyes. Roving eye movements known as nystagmus (involuntary, repetitive movement of the eyes) often appear within the first few months of life and are one of the most recognizable features of LCA.
Children with LCA often develop a habit of poking, pressing, or rubbing their eyes with a finger or knuckle. This is known as the Franceschetti oculodigital sign. The pressure on the eye stimulates the photoreceptor cells and produces phosphenes (brief flashes or sensations of light), which provides sensory input when normal vision is absent. While this behavior is not immediately harmful, repeated and forceful eye rubbing over time may lead to changes in the shape of the eye and should be gently discouraged.
Beyond nystagmus and the oculodigital sign, there are several other symptoms that parents and pediatricians may notice in children with LCA.
- Strabismus: misalignment of the eyes, where one or both eyes turn in, out, up, or down
- Photophobia: unusual sensitivity to bright light, causing a child to squint or avoid lit environments
- Sluggish or absent pupillary responses when a light is shined in the eye
- Hyperopia (farsightedness), which is common across many subtypes of LCA
The degree of vision loss varies among children with LCA. Some children retain limited light perception, while others have no measurable vision at all. The specific gene involved and the nature of the mutation both influence how much vision a child may have.
Treatment Options
Treatment for LCA depends almost entirely on the specific gene involved. For most people with LCA, supportive care and low vision services remain the foundation of management. However, for a subset of patients, gene therapy is now an approved option, and research into additional treatments is advancing rapidly.
Luxturna (voretigene neparvovec) was the first gene therapy approved by the FDA for an inherited disease. It is specifically approved for patients with confirmed mutations in both copies of the RPE65 gene. Luxturna works by delivering a functional copy of the RPE65 gene directly into the retinal cells using a modified, harmless virus as a carrier. A retinal specialist delivers the therapy through a carefully placed injection beneath the retina.
Because RPE65 mutations account for approximately 8% of LCA cases, most people with LCA are not currently eligible for this therapy. Patients must also have enough surviving retinal cells for the treatment to take effect, which is why early diagnosis and timely referral are so important. If your child has an RPE65 mutation, discuss Luxturna eligibility with a retinal specialist as soon as possible.
For LCA caused by CEP290 gene mutations, which account for approximately 15% of cases, researchers have been studying a different approach using CRISPR-based gene editing. Unlike gene therapy, which adds a working copy of a gene, CRISPR editing aims to correct the mutation directly within the retinal cells. Clinical trial results have shown that a meaningful proportion of participants experienced measurable improvements in vision. However, this approach remains experimental and has not yet been approved by the FDA for routine clinical use.
Families whose child has a CEP290 mutation should discuss the possibility of participating in a clinical trial with a retinal specialist who has experience in inherited retinal diseases.
Research into additional forms of LCA continues to move forward. Scientists have developed gene therapy approaches targeting mutations in the NPHP5 gene, which affects the primary cilium in retinal cells. Using laboratory-grown miniature retinas derived from patient cells, researchers have gained important new insights into how this gene functions and how to potentially correct it.
An oral medication that provides a form of vitamin A capable of bypassing a defective enzyme has also been studied in early-phase trials for LCA caused by RPE65 or LRAT mutations. This approach could potentially improve light sensitivity for some patients. All of these treatments remain investigational and are not yet available outside of clinical trials.
For the majority of people with LCA who do not have access to gene therapy, supportive care is the primary approach. These services focus on making the most of remaining vision and supporting independence in daily life.
- Increasing room illumination and using adjustable screens, magnification software, and portable lighting tools
- Working with a low vision consultant who can recommend appropriate assistive devices and adaptive technology
- Orientation and mobility training to help with safe navigation in familiar and unfamiliar environments
- Physical therapy, occupational therapy, and speech therapy to address developmental delays that can result from severe early visual impairment
Starting these services early in childhood makes a meaningful difference in a child's overall development and long-term independence. Early intervention programs are especially valuable during the first few years of life.
What to Expect Over Time
LCA is a lifelong condition, and understanding what the future may look like helps families plan and advocate effectively for their child. The course of LCA varies depending on the gene involved and the nature of the specific mutation.
Most children with LCA have severe vision loss from birth or very early infancy. In some subtypes, vision may remain relatively stable at a limited level for many years. In others, there can be a gradual further loss of remaining vision over time as photoreceptor cells continue to deteriorate. The rate and extent of this progression depend on which gene is affected.
Regular follow-up with a retinal specialist is important even when no specific treatment is available. Ongoing monitoring helps detect any changes in the retina and ensures that low vision services and assistive strategies are updated as your child's needs evolve.
For patients who receive Luxturna, improvements in light sensitivity and the ability to navigate in low-light environments may begin within days to weeks after treatment. Clinical studies showed meaningful gains in functional vision tasks. However, gene therapy does not restore vision to normal levels, and most patients will continue to benefit from low vision support and assistive devices even after treatment.
Long-term outcomes of Luxturna are still being studied, and some research suggests that the benefits may diminish over several years in certain patients. This makes continued follow-up with a retinal specialist essential, and it underscores the importance of ongoing research into longer-lasting treatments.
Living With LCA
Life with LCA involves working closely with a team of medical, educational, and developmental professionals. With the right support and resources, children with LCA can develop strong skills, pursue education, and lead full lives. Families are not alone in this journey.
Early intervention is one of the most powerful tools available. Orientation and mobility training helps children learn to navigate safely in their environment. Occupational therapy supports the development of fine motor skills and independence with daily tasks. Schools can provide accommodations such as large print materials, screen readers, and instruction in Braille. Parents and caregivers can advocate for these services through individualized education plans tailored to their child's specific needs.
Receiving a diagnosis of LCA can bring feelings of grief, worry, and uncertainty. These feelings are entirely natural and valid. Connecting with other families affected by inherited retinal diseases can provide comfort and practical guidance. Organizations such as the Foundation Fighting Blindness and the National Organization for Rare Disorders offer support networks, educational resources, and information about current research.
Genetic counseling is also an important resource for the whole family. A genetic counselor can help parents fully understand the inheritance pattern, assess the risk for future pregnancies, and connect families with appropriate support services in their area.
The field of inherited retinal disease is advancing at a remarkable pace. New gene therapies, gene editing approaches, and other experimental treatments are in various stages of clinical development. Maintaining a relationship with a retinal specialist who has experience with inherited retinal diseases is the best way to stay informed about new opportunities as they emerge. Families can also search clinical trial registries to identify studies that may be relevant to their child's specific genetic diagnosis.
When to See a Specialist
Because LCA is a rare and genetically complex condition, timely access to the right specialist can make a significant difference in outcomes. Knowing when and where to seek specialized care helps families move quickly from diagnosis to support.
Any infant who shows signs of poor visual responsiveness, roving eye movements, nystagmus, or unusual eye rubbing should be referred to a retinal specialist as soon as possible. Early diagnosis allows families to access genetic testing, learn about potential treatment options, and begin the supportive services that are most beneficial when started early in a child's development. Delay in diagnosis can mean missing a window for certain treatments.
Because LCA is rare, families benefit from seeing a retinal specialist with specific experience in inherited retinal diseases. These specialists can coordinate genetic testing, monitor the retina over time, and guide families through the complex and evolving landscape of gene therapy and clinical trials. If your child is found to have an RPE65 mutation, timely referral to a center that offers Luxturna is especially important, as the therapy works best when enough viable retinal cells are still present.
Frequently Asked Questions
These questions address some of the practical concerns families often have after a diagnosis of LCA, including topics not covered in full detail above.
LCA is not included in standard newborn screening programs at this time. However, if both parents are already known to carry a specific LCA gene variant, prenatal genetic testing during pregnancy or preimplantation genetic testing as part of in vitro fertilization may be options worth discussing. Genetic counseling is the best starting point for families considering these options, as a counselor can explain the process and help determine what is appropriate for your specific situation.
No. As of 2026, Luxturna is the only FDA-approved gene therapy for LCA, and it applies only to patients with mutations in both copies of the RPE65 gene, which accounts for a small minority of LCA cases. Research into gene therapy and gene editing for other subtypes, including CEP290 and NPHP5, is ongoing but remains experimental. The best way to find out whether any approved or investigational treatment applies to your child is to review the specific genetic test results with a retinal specialist experienced in inherited retinal diseases.
The degree of vision loss in LCA varies depending on which gene is involved and the nature of the specific mutation. Some children retain limited light perception or some functional vision throughout their lives, while others have very little measurable vision from birth. A retinal specialist who has reviewed your child's genetic results and examined the retina is best positioned to give you the most accurate picture of what to expect. Regardless of the level of vision, a full range of adaptive strategies and low vision services can help maximize independence and quality of life.
Both LCA and retinitis pigmentosa (RP) are inherited retinal diseases that damage photoreceptor cells, and they share some of the same genetic causes. The key difference is when vision problems begin. LCA causes severe vision loss from birth or early infancy, while RP typically begins with night blindness during adolescence or early adulthood and progresses more gradually over decades. In some cases, a mutation in the same gene can cause LCA if severe or RP if milder, which is one reason genetic testing is so valuable in clarifying a diagnosis.
The most direct path is through a retinal specialist with expertise in inherited retinal diseases. These specialists stay current on ongoing and upcoming trials and can assess whether your child's genetic profile and retinal health make them a candidate for a specific study. Families can also search publicly available clinical trial registries using their child's specific gene name as a search term. Patient advocacy organizations focused on inherited retinal diseases maintain regularly updated information about active trials and can be a helpful resource alongside your specialist.
In the short term, the eye-rubbing and pressing behavior associated with LCA is generally not dangerous. It occurs because pressing on the eye stimulates the photoreceptors and creates a brief sensation of light, which can be comforting when normal vision is absent. However, persistent and forceful eye rubbing over months and years can potentially lead to changes in corneal shape or other structural changes in the eye. If you notice frequent or forceful eye rubbing, mention it to your child's retinal specialist so they can monitor for any long-term effects and discuss gentle ways to redirect the behavior.